The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies

Cardiovascular Therapeutics
Barry GumbinerPamela D Garzone

Abstract

Three single-dose and one multiple-dose phase I studies were conducted in subjects with primary hypercholesterolemia to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of bococizumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. The dosing schedules for hypercholesterolemic subjects randomized in the four phase I studies were (1) ascending, single, intravenous (IV) bococizumab (0.3, 1, 3, 6, 12, or 18 mg/kg), or placebo (N = 48; baseline low-density lipoprotein cholesterol [LDL-C] ≥130 mg/dL); (2) single, IV bococizumab (0.5 or 4 mg/kg; no placebo) added to ongoing atorvastatin 40 mg/day (N = 24); (3) single, fixed, subcutaneous (SC) bococizumab (100 or 200 mg), or IV bococizumab (200 mg; no placebo; N = 49; baseline LDL-C ≥130 mg/dL); and (4) weekly IV bococizumab (0.25, 0.5, 1, or 1.5 mg/kg) or placebo for 4 weeks (N = 67; baseline LDL-C ≥130 mg/dL). Bococizumab pharmacokinetics were well characterized following single IV or SC doses and following multiple IV doses. Exposure to single-dose bococizumab increased slightly greater than dose-proportionally and clearance decreased with increasing dose. In the single-dose studies, maximal mean percent reductions from baseline in LDL-C...Continue Reading

References

Jan 29, 2003·Proceedings of the National Academy of Sciences of the United States of America·Nabil G SeidahMichel Chretien
Mar 24, 2006·The New England Journal of Medicine·Jonathan C CohenHelen H Hobbs
Nov 24, 2007·Journal of Lipid Research·Holly E CareskeyRobert J Konrad
Apr 9, 2009·The Journal of Clinical Endocrinology and Metabolism·Susan G LakoskiHelen H Hobbs
Feb 2, 2012·The Journal of Biological Chemistry·Javier Chaparro-RiggersArvind Rajpal
Mar 23, 2012·The New England Journal of Medicine·Evan A SteinGary D Swergold
Nov 2, 2012·The New England Journal of Medicine·Eli M RothEvan A Stein
Jun 9, 2016·Vascular Health and Risk Management·Dirk J BlomPeter P Toth
Jul 21, 2016·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Nicola FerriAlberto Corsini
Aug 9, 2016·Cardiovascular Research·Giuseppe Danilo NorataAlberico L Catapano
Jan 7, 2017·Expert Opinion on Biological Therapy·Nicola FerriMassimiliano Ruscica
Mar 18, 2017·The New England Journal of Medicine·Marc S SabatineUNKNOWN FOURIER Steering Committee and Investigators
Mar 18, 2017·The New England Journal of Medicine·Paul M RidkerUNKNOWN SPIRE Investigators
Mar 18, 2017·The New England Journal of Medicine·Paul M RidkerUNKNOWN SPIRE Cardiovascular Outcome Investigators
Apr 13, 2017·Internal Medicine Journal·Daniel J SchererStephen J Nicholls
May 30, 2017·Expert Opinion on Biological Therapy·Nicola FerriMassimiliano Ruscica
Jun 6, 2017·The New England Journal of Medicine·Darren B TaichmanJoyce Backus

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

© 2022 Meta ULC. All rights reserved